Oscar Health Q4 2025 earnings reflect a market reset the company did not choose—but one it had long anticipated entering 2025. The expiration of enhanced premium tax credits, Medicaid redeterminations flowing into the ACA exchanges, and heightened program integrity efforts altered the risk profile of the individual market in ways that proved punishing for carriers unprepared for volatility.
Oscar’s results reflect that turbulence. Yet embedded in the fourth-quarter commentary was something more consequential: a deliberate repositioning of the business toward structural profitability in 2026 and beyond.
The core question for investors is not whether 2025 was difficult. It was. The more important question is whether Oscar’s growth into 2026 represents risky expansion into a destabilized market—or a disciplined share capture that meaningfully resets margin potential.
Management’s guidance suggests the latter. The numbers demand closer scrutiny.
Earnings Snapshot
Oscar Health Q4 2025 earnings showed 28% revenue growth to $11.7 billion, while the medical loss ratio rose to 87.4% due to elevated risk adjustment transfers.
Adjusted EBITDA declined to negative $280 million, reflecting external morbidity volatility.
Oscar Health Q4 2025 Earnings: Revenue Growth Meets Risk Adjustment Reality
Oscar delivered 28% revenue growth in 2025, with Oscar Health revenue growth 2025 reaching $11.7 billion. Oscar Health membership growth accelerated, scale improved, and Oscar Health SG&A leverage materialized. Yet earnings deteriorated sharply as market morbidity stepped higher and risk adjustment swung against the company.
The year’s financial profile can be summarized as follows:
| Metric | FY 2024 | FY 2025 | YoY Change |
|---|---|---|---|
| Total Revenue | $9.1B (implied) | $11.7B | +28% |
| Medical Loss Ratio | 81.7% | 87.4% | +570 bps |
| SG&A Ratio | 19.1% | 17.5% | -160 bps |
| Loss from Operations | $58M (implied) | $396M | -$338M |
| Adjusted EBITDA | $199M (implied) | -$280M | -$479M |
All financial figures cited throughout this analysis are drawn from Oscar Health’s fourth-quarter and full-year 2025 earnings press release, published February 10, 2026, and earnings call.
The deterioration was driven almost entirely by Oscar Health’s risk adjustment payable. Oscar’s risk transfer payable rose meaningfully as Medicaid redetermination populations entered the exchanges, increasing overall market morbidity.
The company ended the year with risk transfer equal to roughly 18.5% of direct premiums—390 basis points higher than the prior year.
Fourth quarter results magnified the issue. A $275 million increase in risk adjustment accrual, driven by Oscar’s membership skewing healthier relative to the broader market, pushed Q4 MLR to 95.4%.
Favorable prior-period development and health insurance trends partially offset the blow, but the narrative was clear: forecasting market-wide acuity remains the hardest variable in the ACA model.
Importantly, utilization trends themselves were not alarming. Inpatient moderated, pharmacy ran in line with expectations, and outpatient and professional services ticked modestly higher, likely reflecting members accelerating care before subsidy expiration.
The structural issue was not internal cost control; it was relative morbidity positioning inside a net-neutral risk pool.
Management framed 2025 as a “reset year for the industry.” That framing is credible. The real debate is whether Oscar used the reset to improve its competitive position.
Membership Expansion Into a Contracting Market
The ACA individual market contracted approximately 5% year-over-year during open enrollment, reflecting evolving dynamics and landing near 23 million lives. That decline was better than initial fears of a 20–30% drop following subsidy expiration, though management still expects additional attrition as grace periods expire and passive enrollees confront higher premiums.
Against that backdrop, Oscar’s membership surged.
The company reported 3.4 million members as of February 1, 2026, with expectations of approximately 3.0 million paid members by the end of the first quarter. That represents roughly 58% year-over-year growth in paid membership.
This is not market growth. It is a share capture.
Oscar Health’s market share of ACA in its service areas increased from 17% to 30%. Much of this gain appears to have come from competitors retreating, pulling back pricing, or exiting certain geographies amid morbidity uncertainty.
Oscar responded with aggressive broker engagement, targeted plan redesign, and product repositioning to absorb price-sensitive members transitioning off enhanced subsidies.
The metal mix shift illustrates how dramatic the repositioning has been:
| Metal Tier | FY 2024 Mix | FY 2026 Mix |
|---|---|---|
| Bronze | 25% | 39% |
| Silver | 71% | 36% |
| Gold | 4% | 25% |
Silver plans—historically dominant under enhanced subsidies—collapsed in mix. Bronze nearly doubled, and gold increased more than sixfold. The new book is meaningfully rebalanced toward both high-deductible affordability and richer, targeted designs.
The implication is twofold. First, revenue per member month will not simply scale with rate increases due to younger demographics and mix shifts. Second, churn and utilization behavior may not resemble prior metal-based historical experience, as silver enrollees migrate into different cost-sharing dynamics.
Management emphasized that margins across metal tiers are designed to sit within a “relatively tight band,” suggesting underwriting discipline across the mix rather than cross-subsidization.
The question becomes whether the enlarged membership base carries elevated future risk—or whether it creates a scale-driven earnings reset.
From Q3 Expectations to Q4 Reality: What Played Out—and What Didn’t
Oscar’s third quarter 2025 earnings call was framed less as a turning point and more as a checkpoint. Management acknowledged worsening ACA market morbidity trends, elevated risk-adjustment uncertainty, and near-term earnings pressure, while maintaining that the business’s underlying mechanics were tracking as expected.
By the time fourth-quarter results were reported, several of those assertions had either been confirmed or stress-tested, sharpening the 2026 setup.
Utilization Trends Held Beneath the Noise
Management suggested in Q3 that utilization pressure was moderating beneath the headline deterioration in MLR. That expectation largely held. Inpatient utilization remained elevated but continued to decelerate through year-end. Pharmacy trends stayed favorable, and outpatient and professional services ran modestly above expectations rather than accelerating sharply.
The fourth-quarter Oscar Health medical loss ratio shock was not driven by cost inflation; it was driven by risk adjustment.
Risk Adjustment Volatility Materialized as Warned
The Q3 call explicitly cautioned that risk adjustment volatility under the ACA could worsen as additional market data arrived. That risk materialized more forcefully than many investors likely anticipated.
The fourth quarter included a $275 million increase in risk adjustment accrual, pushing full-year risk transfer to roughly 18.5% of direct premiums. In that sense, Q4 validated the warning while clarifying that the volatility was externally driven rather than operational.
Membership Growth Exceeded Midyear Expectations
Management noted in Q3 that membership growth was running ahead of expectations and would likely soften into year-end as SEP dynamics normalized. That pattern held directionally, but the magnitude surprised to the upside.
Paid membership exiting 2025 was stronger than implied by midyear commentary, setting up a materially larger revenue base for 2026 than investors were modeling after the third quarter.
SG&A Leverage Proved Structural, Not Cyclical
The Q3 framing of SG&A leverage as a structural strength proved durable. Despite deteriorating earnings optics, administrative efficiency continued to improve into the fourth quarter.
This reinforced management’s claim that fixed-cost leverage and automation gains are embedded in the model rather than dependent on favorable market conditions.
Q3 Expectations vs. Q4 Outcomes
| Theme | What Management Indicated in Q3 | What Q4 Ultimately Showed |
|---|---|---|
| Utilization trends | Moderating beneath headline MLR pressure | Deceleration held; no cost spike |
| Risk adjustment | Potential for further deterioration | Large accrual increase confirmed |
| Membership trajectory | Strong growth, likely to soften | Growth remained stronger than expected |
| SG&A leverage | Structural improvement continuing | Further leverage realized |
| Market morbidity | Signs of stabilization emerging | Stabilization fragile, lagging |
What the Comparison Clarifies
The takeaway is not that the Q3 framework was wrong, but that the fourth quarter compressed multiple years of risk-adjustment learning into a single reporting period. What appeared as theoretical volatility in Q3 became realized volatility in Q4.
Importantly, none of the fourth-quarter developments undermines the core 2026 margin thesis laid out in the third quarter. If anything, they reinforce the logic of resetting pricing, absorbing volatility early, and scaling into a more rational competitive landscape.
In that sense, Q4 did not contradict the confidence expressed in Q3. It tested it and clarified the cost of getting there.
The volatility described here builds on trends discussed in Oscar Health Q3 2025 earnings coverage.
2026 Guidance: The Margin Expansion Thesis
Oscar Health’s profitability outlook for 2026 is bold. Revenue is projected between $18.7 billion and $19.0 billion—approximately 61% growth at the midpoint. More importantly, the medical loss ratio is expected to improve to 82.4%–83.4%, representing roughly 450 basis points of year-over-year improvement.
Oscar Health SG&A leverage is projected to continue improving, with the ratio declining to 15.8%–16.3%, an additional ~140 basis points of improvement.
Taken together, these assumptions drive operating earnings guidance of $250–$450 million, implying a year-over-year swing of nearly $750 million.
The core financial reset can be framed succinctly:
| Metric | FY 2025 | FY 2026 Guidance Midpoint | Change |
|---|---|---|---|
| Revenue | $11.7B | ~$18.85B | +61% |
| MLR | 87.4% | ~82.9% | -450 bps |
| SG&A Ratio | 17.5% | ~16.0% | -150 bps |
| Earnings from Operations | -$396M | ~$350M | +~$750M |
This is not an incremental improvement. It is a structural inflection.
The credibility of this outlook rests on three assumptions:
- Risk adjustment accrual stabilizes at roughly 20% of direct premiums, with better market visibility through Wakely data initiatives.
- New membership acuity tracks modestly better than pricing assumptions, aided by third-party clinical data integration.
- Elevated churn primarily affects zero-premium-to-paid-premium transitions rather than stable broker-managed renewals.
Management’s framing reinforces this confidence.
“We have been preparing for the expiration of the enhanced premium tax credits for some time and took deliberate actions in 2025 to position the business for profitable growth and improved financial performance.”
The pivot is clear: 2025 absorbed morbidity volatility; 2026 captures pricing reset and scale leverage.
What the 2026 Guidance Signals
Oscar Health Q4 2025 earnings positioned 2026 as a structural inflection year, with projected 61% revenue growth and medical loss ratio improving toward 83%, implying a nearly $750 million operating swing.
The AI Efficiency Narrative: Cost Structure Compression
Unlike some insurers that frame AI as a front-end engagement tool, Oscar’s narrative centers on operational leverage. The administrative cost ratio improved by 160 basis points in 2025 despite 28% revenue growth. Further leverage is projected in 2026.
The company highlighted two notable internal metrics: a 67% reduction in response times for care guides during peak enrollment via agentic AI tools, and 86% resolution of member inquiries through its Oswell digital health agent.
While the long-term competitive impact remains uncertain, the near-term financial implication is straightforward: fixed-cost leverage combined with variable automation reduces the marginal administrative cost per member.
This matters more at 3 million lives than at 2 million.
Scale converts technology investment from experimentation into operating margin.
Risk Adjustment: The Persistent Wildcard
Despite improved forecasting inputs, risk adjustment volatility, ACA remains structurally elevated because it depends on relative morbidity positioning versus the broader market. Oscar’s healthier-than-market skew in late 2025 produced the $275 million Q4 accrual increase that defined the year.
Management acknowledged the asymmetry:
“We’re quite good at projecting our own book… where we do get surprised is how the market moves in ways that we can’t see.”
The expectation for 2026 is a risk adjustment of approximately 20% of direct premiums, slightly higher than in 2025. That implies management is not assuming favorable positioning—only stabilized dynamics.
The key subtlety is that Oscar’s younger average age (38, one year younger year-over-year) simultaneously lowers expected utilization while increasing risk adjustment payable. The company is effectively choosing demographic growth and accepting transfer payments as a structural cost of scale.
If underwriting discipline holds and third-party data improves acuity targeting, this tradeoff may be rational. But the model’s fragility to systemic morbidity shifts remains the central structural risk.
Capital Position and Balance Sheet Flexibility
Oscar ended 2025 with $5.5 billion in cash and investments, underscoring Oscar Health’s capital surplus and balance sheet flexibility, including $414 million at the parent level. Insurance subsidiaries held approximately $1 billion in surplus capital, of which $315 million was categorized as excess.
The company raised $410 million in convertible notes due 2030 and secured a $475 million revolving credit facility in 2025 to support growth. Regulatory capital requirements—approximately $50 million per $1 billion of premiums—appear manageable given the projected 2026 revenue base.
Capital strength does not eliminate underwriting risk, but it reduces solvency anxiety during market turbulence. That distinction is meaningful.
The Behavioral Question: Will Members Stay?
Perhaps the most uncertain dynamic for 2026 is behavioral rather than actuarial.
Roughly 400,000 members are expected to roll off by the end of Q1, largely representing passive renewals transitioning from zero-premium to paid-premium plans. Payment rates among actively engaged members remain stable.
The question is whether members facing higher deductibles and out-of-pocket exposure will maintain coverage as they begin using services.
Management articulated the tension candidly: Americans increasingly view healthcare as their largest household expense. Fear of financial ruin may sustain coverage even under affordability strain. But high deductibles could produce mid-year attrition.
Oscar’s guidance assumes ACA enrollment churn dynamics revert toward pre-ARPA levels—approximately 1%–2% per month after Q1. If that holds, the membership scale remains durable. If behavioral attrition accelerates, revenue and MLR assumptions could face pressure.
This is the real macro overlay: the elasticity of demand for individual market insurance in a post-subsidy environment.
Strategic Extensions: ICRA and Lifetime Value
Beyond near-term profitability, management emphasized ICRA (Individual Coverage Health Reimbursement Arrangements) as a longer-duration growth vector.
The company sees opportunity not only in capturing insured members but in facilitating employer transitions to defined contribution models, generating brokerage and administrative revenue streams independent of risk capital.
While still immaterial to earnings, the strategic logic is clear: decouple healthcare purchasing from traditional employer group structures and deepen direct-to-consumer relationships over time.
The ambition is to extend lifetime member value across product redesigns, lifestyle plans, and defined contribution funding models. Whether that vision scales meaningfully remains uncertain, but it aligns with Oscar’s consumer-centric brand identity.
Reframing the Core Question
Oscar Health Q4 2025 earnings, in isolation, appear discouraging, marked by higher losses, greater volatility, and risk-adjusted surprises, and the company’s 2025 performance clearly reflects those pressures.
Yet, viewed as a transition year, the numbers suggest something different: a repricing of the individual market that advantaged carriers willing to underwrite aggressively, driving competitor retrenchment.
The 2026 guide is not modest. It assumes disciplined execution across pricing, retention, acuity management, and cost control. A $750 million swing in operating earnings is material.
If management is correct that market morbidity has stabilized and that scale now produces structural SG&A leverage, Oscar may finally cross the profitability threshold that has eluded it since inception.
If risk adjustment volatility re-emerges or behavioral churn exceeds assumptions, the margin expansion thesis weakens.
The individual ACA market remains inherently dynamic. Oscar’s strategy is to grow into that volatility rather than retreat from it.
The central question now becomes clearer: has Oscar reached sufficient scale and pricing discipline to convert market share gains into durable operating earnings—or is this simply the next chapter in a structurally volatile underwriting cycle?
2026 will likely answer that question decisively.
Key Takeaways
Oscar Health Q4 2025 earnings reflect an externally driven reset year shaped primarily by risk adjustment volatility rather than operational deterioration.
Revenue growth remained strong despite market contraction, signaling meaningful share capture within the ACA individual market.
The 2026 guide represents a structural margin inflection built on pricing resets and scale-driven SG&A leverage.
Risk adjustment remains the central structural wildcard within the business model.
Membership durability may determine whether projected margin expansion fully materializes.
Capital strength reduces solvency concerns but does not eliminate underwriting sensitivity.
Get More Earnings Breakdowns and Investor Insights
This site is built for investors who want straightforward, in-depth breakdowns of earnings calls—without the jargon. Whether you follow SoFi, Amazon, Dutch Bros, or other high-growth names, we’ve got you covered. Explore our latest posts and stay tuned—new recaps and insights drop regularly.
Check out our dedicated Oscar Health page for all the latest posts and deep dives, from earnings breakdowns to ongoing coverage.
Written by Bryan Smith, creator of Straight From the Call.
I break down earnings calls so you don’t have to. Clear takeaways, no fluff — just the stuff investors care about.
This post is for informational and educational purposes only. It does not constitute financial, investment, or legal advice. Always do your own research or consult a licensed professional before making financial decisions. For the full policy, see our Not Investment Advice & Disclosure Statement.